DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Roszet is a drug marketed by Althera Pharms and is included in one NDA. There are two patents protecting this drug.
The generic ingredient in ROSZET is ezetimibe; rosuvastatin calcium. There are twenty-four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ezetimibe; rosuvastatin calcium profile page.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be May 1, 2033. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
DrugPatentWatch® Estimated Generic Entry Opportunity Date for ROSZET
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.